CDTX Latest Headlines

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Phase 3 Antiviral Candidate CD388

Market Chameleon (Fri, 14-Nov 10:29 AM)

Merck’s $9.2 Billion Cidara Therapeutics Acquisition Highlights High-Stakes Bet on Universal Flu Prevention

Market Chameleon (Fri, 14-Nov 7:05 AM)

Cidara Therapeutics Sets Spotlight on Phase 2 CD388 Data at ID Week 2025—Fast Track Status and Universal Influenza Prevention Drive Attention

Market Chameleon (Mon, 13-Oct 8:48 AM)

FDA Grants Breakthrough Therapy Status to CD388: Cidara Advances Novel Influenza Prevention for High-Risk Adults

Market Chameleon (Thu, 9-Oct 8:42 AM)

Cidara Therapeutics Secures Up to $339M BARDA Award for Universal Influenza Preventative CD388

Market Chameleon (Fri, 3-Oct 9:13 AM)

Cidara’s Accelerated Phase 3 Plan for CD388 Could Double Eligible Patients for Influenza Prevention

Market Chameleon (Wed, 24-Sep 11:16 AM)

Cidara Therapeutics Expands Phase 3 CD388 Trial to Over 100 Million Potential Patients After FDA Guidance

Market Chameleon (Wed, 24-Sep 8:41 AM)